CytoDyn (OTCMKTS:CYDY) Trading Up 4.4% - Here's What Happened

Key Points

• CytoDyn Inc. experienced a significant increase in its stock price, rising 4.4% to $0.29 during mid-day trading.
• The company has a market capitalization of $360.16 million and a price-to-earnings ratio of 28.75.
• CytoDyn is involved in developing treatments for various conditions including COVID-19 and HIV through its monoclonal antibody, leronlimab.

CytoDyn Inc. (OTCMKTS:CYDY - Get Free Report) shot up 4.4% during mid-day trading on Monday . The stock traded as high as $0.30 and last traded at $0.29. 2,058,801 shares changed hands during trading, an increase of 36% from the average session volume of 1,511,574 shares. The stock had previously closed at $0.28.

CytoDyn Stock Performance

The firm has a market capitalization of $360.16 million, a price-to-earnings ratio of 28.75 and a beta of 1.23. The business's 50 day moving average is $0.30 and its 200-day moving average is $0.28.

CytoDyn (OTCMKTS:CYDY - Get Free Report) last released its quarterly earnings results on Friday, July 25th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter.

About CytoDyn

CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.